Syneron Bio Raises $150M for Peptide Drug Discovery

Syneron Bio, a pioneer in intelligent platform-driven macrocyclic peptide drug discovery, has successfully concluded a substantial $150 million Series B financing round. This significant capital infusion is set to propel the company's innovative Synova™ platform and accelerate its pipeline of novel therapeutics across critical disease areas.

The funding was spearheaded by a prominent international life-science fund, with significant co-lead participation from Decheng Capital and CDH VGC. The round attracted a diverse and influential group of investors, underscoring strong market confidence in Syneron Bio's technological advancements and therapeutic potential. Notable new backers include a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA), True Light Capital (an independent, wholly-owned subsidiary of Temasek), Qiming Venture Partners, BioTrack Capital, and several well-regarded industrial investors.

Reinforcing the company's trajectory, existing shareholders demonstrated continued conviction through their participation. This includes strategic partners such as AstraZeneca, alongside LAV, Sinovation Capital, 5Y Capital, GL Ventures, Biotech Development Fund, and Lenovo Capital, among others. This broad support base highlights a shared vision for Syneron Bio's role in shaping the future of peptide-based medicine.

The newly acquired capital will be strategically deployed to further enhance the capabilities of Syneron Bio's proprietary Synova™ platform. This intelligent, high-throughput system is designed to dramatically improve the efficiency and success rates of discovering macrocyclic peptides, a class of molecules with immense therapeutic promise due to their stability and binding affinity. Furthermore, the funds will accelerate the advancement of Syneron Bio's diverse pipeline programs, moving them towards crucial clinical development stages.

Dr. Frank Zhang, Founder and Chief Executive Officer of Syneron Bio, expressed his gratitude for the overwhelming support. "We are honored by the recognition from such a distinguished cohort of global healthcare funds, venture capital firms, multinational corporations, and sovereign wealth funds," stated Dr. Zhang. "This financing fortifies our financial position, enabling us to expedite the development of our core pipeline programs targeting oncology, autoimmune disorders, metabolic diseases, and rare conditions. Simultaneously, our Synova™ platform will continue its evolution, enhancing drug discovery efficiency. We are committed to delivering innovative therapies to address significant unmet medical needs worldwide."

The macrocyclic peptide market is experiencing robust growth, driven by advancements in drug discovery technologies and the increasing demand for more targeted and effective treatments. Syneron Bio's focus on an intelligent, platform-driven approach positions it advantageously within this dynamic sector. The company's ability to attract such a high-caliber investor syndicate, including sovereign wealth funds and established pharmaceutical players, signals a strong belief in its scientific foundation and commercial potential to deliver next-generation therapeutics.